Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C5a peptidase (ScpA) of Streptococcus pyogenes is a highly specific, cell-surface endopeptidase and virulence factor that cleaves the His-Lys bond in the complement component C5a, thereby inactivating its chemotactic and pro-inflammatory functions and blunting neutrophil recruitment to sites of infection. ScpA is also capable of cleaving C3 and C3a, expanding its role in disarming complement-driven host defense. Structurally, ScpA is a multidomain enzyme with a signal peptide, an N-terminal subtilisin-like protease domain, fibronectin type III domains, and cell wall anchoring features; it is expressed on the bacterial surface and functions both enzymatically and as an adhesin/invasin for host interactions. Antibodies targeting ScpA can neutralize its function and have shown protection in animal models, making ScpA a promising candidate for vaccine development against group A streptococcal diseases.
Proteolysis of C5a (and C3, C3a) to reduce neutrophil chemotaxis and impair host immune response (Targeting the enzyme, e.g., by vaccination, elicits neutralizing antibodies that block this function, restoring immune recruitment to the site of infection)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C5a peptidase of Streptococcus pyogenes (ScpA).